ARTICLE | Clinical News
Spinraza regulatory update
April 26, 2017 6:57 PM UTC
EMA’s CHMP recommended approval of an MAA from Biogen for Spinraza nusinersen to treat spinal muscular atrophy (SMA). The product has Orphan Drug designation and is under accelerated assessment in the...
BCIQ Target Profiles